Log In
Print
BCIQ
Print
Print this Print this
 

ledipasvir (GS 5885, GS-5885)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionNS5A inhibitor
Molecular Target HCV NS5A protein
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotype 1 infection; Treat hepatitis C virus (HCV) infection in cirrhosis
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today